Washington University School of Medicine in St. Louis | Strategic Alliance Partners

Latest from Washington University School of Medicine in St. Louis


Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and Anemia

October 20, 2023

Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.

Dr Zhou on the Use of Combination Therapies in Myelofibrosis

October 13, 2023

Amy W. Zhou, MD, discusses combination therapies with ruxolitinib that may contribute to the treatment paradigm for patients with myelofibrosis, highlighting the importance of continued research with phase 3 confirmatory trials for patients with this disease.

Dr Zhou on the Evaluation of Combination Therapies With Ruxolitinib in Myelofibrosis

September 28, 2023

Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.

Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL

September 14, 2023

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.